Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study. (PubMed, Ann Oncol) - Sep 12, 2026 - "Iza-bren exhibited a generally tolerable safety profile and demonstrated clinically meaningful antitumor activity across three major subtypes of heavily pretreated metastatic breast cancer."
Clinical • Journal • P1 data • Breast Cancer • Cerebral Hemorrhage • CNS Disorders • Febrile Neutropenia • Hematological Disorders • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Interstitial Lung Disease • Neutropenia • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor • Triple Negative Breast Cancer • EGFR • ERBB3 • HER-2
|
|
C Wang; F Xu; G Jin; H Zhou; H Zhu; J Cui; J Wu; J Zhang; K Wang; M Sun; Q Wen; S Xiao; T Sun; W Chen; W Xie; X Wang; Y Chen; Y Du; Y Meng; Y Shi; Y Sun; Y Wang; Y Zhu; Z Wang; Z Zhuang
|